Clinical Fiducial Trial Information Sheet:
Evaluation of a liquid fiducial marker for the creation of a planning target volume in dogs with post-resection soft tissue sarcomas
Statement of Intent: PetCure Oncology is currently recruiting participants for a prospective study evaluating the effectiveness of stereotactic radiosurgery (SRS) in the treatment of incompletely resected, grade 2 soft tissue sarcoma of the skin and subcutaneous tissues in dogs. Specifically, the study is intended to evaluate the utility of PetXmark™, a liquid fiducial marker that incorporates sucrose acetate isobutyrate, X-SAIB (Iodinated sucrose acetate isobutyrate) and EtOH in the creation of a planning target volume.1
How to Enroll: Fill out the enrollment form below or download our printable enrollment form.
Additional Information: Interested in learning more about the trial? Email our Clinical Trials Coordinator, Brandy Banks, at ClinicalTrials@PetCureOncology.com.
Hypothesis: Injection of PetXmark™ liquid fiducial along the scar of a marginally resected soft tissue sarcoma will allow for the creation of an objectively based planning target volume (PTV) that can then be treated with single-fraction SRS, maximizing local control with minimal acute or delayed radiation toxicity.
PetCure Oncology is interested in better defining the role of SRS in the treatment of dogs with incompletely resected soft tissue sarcomas. Currently, there are no controlled, prospective studies in the veterinary literature that define the risks and benefits of SRS for incompletely resected sarcomas. To facilitate case accrual, PetCure Oncology will:
- Provide an SRS video consult free of charge
- Treat the animal for the same costs associated with conventionally fractionated radiation therapy
- Provide the 6- and 18-month follow-up CT free of charge
- Absorb the cost of having an autopsy performed for animals that die after study enrollment, if deemed necessary by PetCure Oncology
Any dog with a microscopically incompletely resected soft tissue sarcoma is potentially eligible for study entry provided they meet all the following requirements:
- Histologically is confirmed as a grade 2 soft tissue sarcoma. This includes a diagnosis of:
- Peripheral nerve sheath tumor
- Spindle cell sarcoma
- Biopsy slides used to confirm the diagnosis must be reviewed by a single pathologist to determine eligibility based on grade
- Study subjects must have a simple (linear) resection scar <15cm in length. Large, complex scars following reconstructive surgery are exclusionary
- Complete reference lab bloodwork with concurrent urinalysis must be available and less than four weeks old at the time of SRS treatment
- Diagnostic CT scan of the thorax, or three-view thoracic radiograph, has been performed. Evidence of metastatic disease is exclusionary for this study, but alternative treatment paths may be available
- Significant co-morbidities that would impact the animal’s ability to tolerate/survive multiple anesthetic events are exclusionary. Whether or not a particular abnormality constitutes a “significant co-morbidity” will be determined by PetCure Oncology
- Caregiver has signed informed consent confirming that they understand this is an ongoing clinical study to better define the role of SRS in the treatment of incompletely resected soft tissue sarcomas in dogs
- Caregiver agrees to follow the prescribed follow-up procedure, including repeat CT scans at six and 18 months post-treatment
- Caregiver consents to an autopsy for any animal that dies following enrollment in the study, if deemed necessary by PetCure Oncology
Traditional dogma in radiation therapy has held that stereotactic radiosurgery (SRS) fractionation is not possible unless there is gross residual disease to target. In cases where animals have had their tumor resected down to microscopic residual disease, the typical recommendation would be to initiate a course of CFRT.
CFRT is delivered in 15-21 small fractions on a M-F or M-W-F basis, depending on the protocol being used. For veterinary radiation therapy (RT) patients, each one of these fractions is accompanied by an anesthetic event, leading some families to forgo post-operative radiation. Unfortunately, a large percentage of these animals will experience regrowth of their cancer. In one study, this occurred at a median of approximately seven months after the original surgery.2
Hypofractionated protocols have been used to treat marginally resected tumors with a good expectation of local control.3,4 Stereotactically delivered radiation should, in theory, improve this local control rate even further by delivering a higher, more precisely targeted dose of radiation intended to cure in 1-3 consecutive day fractions. Integral to this is the ability to define a planning target volume and to deliver a dose of radiation to that target volume that meets the fractionation and target dose metrics consistent with stereotactic radiosurgery. In fact, SRS has been used to treat resection sites in people with brain metastases. This strategy has resulted in improved local control with minimal radiation-induced morbidity, and supports the use of SRS to treat marginally resected disease, even when it is embedded in a critical normal structure such as brain.5-8
PetXmark is a liquid fiducial marker that can be injected along a surgical incision or painted into a resection cavity for later imaging.1 It is a stable and non-toxic compound, does not migrate after injection, and is intended to provide at least two months of stable, reproducible tissue marking that is visible on CT scan.9,10 Prior to the launch of this study, PetCure Oncology conducted a pilot study of 20 dogs whose treatment plans were created using the PetXmark liquid fiducial marker. No acute toxicities, local failures, or geographic misses were observed.
This is a prospective single arm clinical study. All animals are treated on protocol with a single 20Gy fraction. Clinical target volume (CTV) is delineated using PetXmark injected at 1cm intervals along the resection scar. The PTV will incorporate a 1cm margin applied to the PetXmark-defined CTV. A 3mm skin sparing margin will be applied within the planning structure set, and the skin metrics will be within the limits established by the PetCure Oncology Scientific Advisory Board (DMax <26Gy, 10cc <23Gy). A Case Report Form (CRF) will be completed for each animal enrolled in the study. The CRF will be completed by the treating radiation oncologist, and will become part of the permanent medical record. A completed copy of the CRF will be provided to Nanovi for their records.
This study is designed to research how animals with incompletely resected grade 2 soft tissue sarcoma will respond to SRS. PetCure Oncology believes that the treatment will be safe and effective, and this study is designed to test this hypothesis. We appreciate your willingness to participate in the study, and we commit to retreat study participants at no cost to the owner in the event of:
- Early Local Failure – Defined as recurrence within the treatment field within two years following SRS treatment
- Geographic Miss – Defined as regrowth at the periphery of the treatment field within two years following SRS treatment
If you have questions about enrollment criteria or would like to refer an animal for evaluation/inclusion in the study, contact:
If you have questions about the study design or the protocol for treatment, contact:
- Rydhög JS, Mortensen SR, Larsen KR, Clementsen P, Jølck RI, Josipovic M, Aznar M, Specht L, Andresen TL, Rosenschöld PM, Persson GF: Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer, Radiotherapy and Oncology (2016); Volume 121, Issue 1, Pages 64–69.
- Elmslie RE, Glawe P and Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcoma. J Vet Intern Med, 2008; 22:1373-1379.
- Hypofractionated radiation therapy for the treatment of microscopic canine soft tissue sarcoma.
Kung MB, Poirier VJ, Dennis MM, Vail DM, Straw RC.
Vet Comp Oncol. 2014 Nov 13. doi: 10.1111/vco.12121. [Epub ahead of print]
- Intentional marginal excision of canine limb soft tissue sarcomas followed by radiotherapy.
Demetriou JL, Brearley MJ, Constantino-Casas F, Addington C, Dobson J.
J Small Anim Pract. 2012 Mar;53(3):174-81. doi: 10.1111/j.1748-5827.2011.01186.x.
- Survival was Significantly Better with Surgical/Medical/Radiation Co-interventions in a Single-Institution Practice Audit of Frameless Stereotactic Radiosurgery.
Taggar A, MacKenzie J, Li H, Lau H, Lim G, Nordal R, Hudson A, Khan R, Spencer D, Voroney JP.
Cureus. 2016 May 17;8(5):e612. doi: 10.7759/cureus.612.
- Postoperative Stereotactic Radiosurgery Using 5-Gy × 5 Sessions in the Management of Brain Metastases.
Abuodeh Y, Ahmed KA, Naghavi AO, Venkat PS, Sarangkasiri S, Johnstone PA, Etame AB, Yu HH.
World Neurosurg. 2016 Jun;90:58-65. doi: 10.1016/j.wneu.2016.02.007.
- Postoperative Stereotactic Radiosurgery vs Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study.
Rao G, Ahmed S, Hess K, Mahajan A.
Neurosurgery. 2016 Aug;63 Suppl 1:184. doi: 10.1227/01.neu.0000489784.83922.17.
- Hypofractionated Stereotactic Radiosurgery and Radiotherapy to Large Resection Cavity of Metastatic Brain Tumors.
Lima LC, Sharim J, Levin-Epstein R, Tenn S, Teles AR, Kaprealian T, Pouratian N.
World Neurosurg. 2017 Jan;97:571-579. doi: 10.1016/j.wneu.2016.10.076.
- Acknowledgement: Data obtained from clinical investigation no. 310-01 ”Proof of concept study evaluating safety and performance of a gel marker (PetXmark™) used for image guidance in deep inspiration breath- hold radiotherapy (DIBH IGRT) in patients with locally advanced non-small cell lung cancer (NSCLC)”. Rigshospitalet, Copenhagen, Denmark. Principle Investigator: Prof. Lena Specht, MD.
- Acknowledgement: Data obtained from clinical investigation no. 310-02 ”Proof of concept study evaluating safety and performance of a gel marker (PetXmark™) used for image guided radiotherapy (IGRT) of esophageal cancer”. Rigshospitalet, Copenhagen, Denmark. Principle Investigator: Prof. Lena Specht, MD.